Merck adds oncolytics combo study to its huge Keytruda effort

Merck ($MRK) and Houston-based DNAtrix have struck a deal to collaborate on a combination study of the pharma giant's checkpoint inhibitor Keytruda with the biotech's oncolytics immunotherapy DNX-2401. No deal terms were disclosed, but longtime observers will note that Merck R&D chief Roger Perlmutter was an early advocate of oncolytics' potential when he was running the research arm at Amgen ($AMGN) (now pursuing an approval for T-Vec). The oncolytics approach is designed to spur a viral attack that can implode cancer cells while launching an immune system attack. And Perlmutter has maintained a huge commitment to expanding on a pioneering approval for Keytruda. A spokesperson for Merck notes that the company is conducting more than 130 clinical trials for Keytruda across more than 30 tumor types. There are 80 ongoing and planned combo studies. Investigators have been enrolling more than 22,000 patients for the monotherapy and in combination with other therapies. Release

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.